COMP <GO>
USPH vs MRK // GROSS PROFIT MARGIN
U.S. Physical Therapy Inc. (NYSE) VS. Merck & Company Inc. (NYSE) • 15-METRIC TALLY: USPH 4
— MRK 9
▲ GROSS PROFIT MARGIN LEADER: MRK
LAST: $86.57 (+1.47%) • MKT CAP: $1.29B
gross-margins
19.20%
LAST: $146.33 (+3.83%) • MKT CAP: $361.02B
gross-margins
74.80%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (USPH VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | USPH | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin ACTIVE | 19.20% | 74.80% | -55.60 | MRK | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 11.50% | 20.70% | -9.20 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation | 16.3x | 15.3x | +1.00 | MRK | /valuation <GO> |
| Free Cash Flow Yield | 5.81% | 3.42% | +2.39 | USPH | /fcf-yield <GO> |
| Operating Margin | 11.10% | 34.30% | -23.20 | MRK | /operating-margins <GO> |
| Net Profit Margin | 5.10% | 28.10% | -23.00 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | 16.30% | 1.30% | +15.00 | USPH | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 2.12% | 2.26% | -0.14 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.94 | 5.19 | -2.25 | MRK | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | USPH | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 52.3 | 51.7 | +0.55 | USPH | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.92 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 27.4x | 18.4x | +9.00 | MRK | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.29B | $361.02B | -$359.73B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | USPH REV | MRK REV | USPH GROSS % | MRK GROSS % | USPH FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $781.0M | $65.01B | 19.2% | 74.8% | $75.1M | $12.36B |
| FY 2024 | $671.3M | $64.17B | 18.5% | 76.3% | $74.9M | $18.10B |
| FY 2023 | $604.8M | $60.12B | — | — | $82.0M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
USPH // BETA —
MRK // BETA 0.92